US FDA approves Sweden-based Calliditas' kidney disease drug
20/12/2023 21:20
Dec 20 (Reuters) - The U.S. Food and Drug Administration granted full approval to Swedish drugmaker Calliditas Therapeutics' CALTX.ST drug to treat rare kidney disease IgA Nephropathy, the company said on Wednesday. (Reporting by Mariam Sunny, Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli) ((Christy.Santhosh@thomsonreuters.com))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations